Gvoke (glucagon) is a brand-name drug prescribed for extremely low blood sugar from diabetes in adults and some children. Gvoke comes as a subcutaneous injection that’s used as needed. Gvoke is ...
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology ...
Xeris Pharmaceuticals, a specialty pharmaceutical company, is introducing Gvoke HypoPen (glucagon injection) for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years ...
Hello, everyone, and welcome to the Xeris Biopharma First Quarter 2024 Financial Results Conference Call and Webcast. My name is Seth, and I'll be the operator for your call today. [Operator ...
SHIRLEY, N.Y., Aug. 27, 2025 /PRNewswire/ -- American Regent, Inc. ® is pleased to announce the commercial launch and availability of Gvoke VialDx™ (glucagon injection). Gvoke VialDx (glucagon ...
CHICAGO, March 17, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...
Approximately 78% of commercially insured and Medicare lives have unrestricted access to Gvoke HypoPen at launch Easy to use: premixed and ready-to-go A reliable method of delivery: 99% of people were ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...
GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for pediatric and adult patients with diabetes ages 2 years and above or caregivers to rapidly treat severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback